Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology
暂无分享,去创建一个
Gerhard Müller | Doris Hafenbradl | Lars Neumann | Allegra Ritscher | G. Müller | D. Hafenbradl | L. Neumann | Allegra Ritscher
[1] Adrian H Elcock,et al. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase. , 2006, Journal of molecular biology.
[2] G. Zaman,et al. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors. , 2006, Assay and drug development technologies.
[3] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[4] Tudor I. Oprea,et al. Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.
[5] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[6] G. Müller,et al. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition , 2008, Expert opinion on drug discovery.
[7] L. Tong,et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.
[8] G. Müller,et al. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition , 2008, Expert opinion on drug discovery.
[9] Christopher W Murray,et al. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.
[10] D. Swinney,et al. Biochemical Mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety. , 2006, Current topics in medicinal chemistry.
[11] D. Osguthorpe,et al. Structure and energetics of ligand binding to proteins: Escherichia coli dihydrofolate reductase‐trimethoprim, a drug‐receptor system , 1988, Proteins.
[12] C. Pargellis,et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 796. , 2003, Bioorganic & medicinal chemistry letters.
[13] Ian A. Watson,et al. Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.
[14] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[15] Kerim Babaoglu,et al. Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.
[16] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[17] D. Swinney,et al. Biochemical mechanisms of drug action: what does it take for success? , 2004, Nature Reviews Drug Discovery.
[18] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.